Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Montserrat Arnán SangermanAinhoa Fernández MorenoAntonio García QuintanaCarolina García-VidalMaría Teresa Olave RubioMaría Del Mar Tormo DíazMeritxell VendranasGabriela Rodriguez MaciasPublished in: Expert review of hematology (2022)
Midostaurin is the first agent showing significant survival benefit when combined with chemotherapy in FLT3-mutated AML patients. Optimal use of midostaurin should be a priority, being essential to know the interactions with other drugs like strong CYP3A4 inhibitors or inducers, which are particularly used in the concomitant treatment of AML patients and may increase toxicity or decrease therapeutic benefit. The active role of hematologists and nursing teams is crucial to ensure patient adherence to midostaurin treatment and to minimize adverse effects by administrating the optimal dose for each situation.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- ejection fraction
- chronic kidney disease
- healthcare
- peritoneal dialysis
- allogeneic hematopoietic stem cell transplantation
- mental health
- type diabetes
- oxidative stress
- patient reported outcomes
- radiation therapy
- squamous cell carcinoma
- patient reported
- skeletal muscle